Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 23 for:    Estropipate

Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Pre-post Omentectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03258307
Recruitment Status : Completed
First Posted : August 23, 2017
Last Update Posted : August 6, 2019
Sponsor:
Information provided by (Responsible Party):
Isa Aykut Ozdemir, Istanbul Training and Research Hospital

Brief Summary:

Omentum is adipose tissue lying under inner anterior wall Omentectomy is routine procedure in treatment of gynecological malignancy especially ovarian cancer and some advanced stage endometrial cancer. Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone secrete from adipose tissue. These regulate matabolic process.

We aimed comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone levels derivated from adipose tissue pre-postoperatively in patient diagnosed with gynecological malignancy performed omentectomy or not


Condition or disease Intervention/treatment Phase
Gynecologic Cancer Other: Preoperative level Not Applicable

Detailed Description:

Omentum is adipose tissue lying under inner anterior wall Omentectomy is routine procedure in treatment of gynecological malignancy especially ovarian cancer and some advanced stage endometrial cancer. Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone secrete from adipose tissue. These regulate matabolic process.

We aimed comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone levels derivated from adipose tissue pre-postoperatively in patient diagnosed with gynecological malignancy performed omentectomy or not. Blood sample will study after 4000 rpm centrifugal for 10 minutes


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Health Services Research
Official Title: Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Derivated From Adipose Tissue Pre-postoperatively in Patient Diagnosed With Gynecological Malignancy Performed Omentectomy or Not
Actual Study Start Date : February 1, 2017
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: omentectomy
Preoperative
Other: Preoperative level
Blood sample
Other Name: Postoperative level

Omentectomy
Postoperative
Other: Preoperative level
Blood sample
Other Name: Postoperative level

No omentectomy
Preoperative post operative
Other: Preoperative level
Blood sample
Other Name: Postoperative level




Primary Outcome Measures :
  1. with omentectomy group [ Time Frame: 1 year ]
    Pre-postoperative levels of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone

  2. No omentectomy group [ Time Frame: 1 year ]
    Pre-postoperative levels of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • gynecologic malignancy, staging surgery with or without omentectomy

Exclusion Criteria:

  • not accept inclusion to trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03258307


Locations
Layout table for location information
Turkey
Bakirkoy Dr Sadi Konuk Training and Research Hospital
İstanbul, Turkey, 34000
Sponsors and Collaborators
Istanbul Training and Research Hospital

Layout table for additonal information
Responsible Party: Isa Aykut Ozdemir, Head of Department of Gynecologic Oncology Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul Training and Research Hospital
ClinicalTrials.gov Identifier: NCT03258307     History of Changes
Other Study ID Numbers: 900
First Posted: August 23, 2017    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not share other researchers due to participant individual preference but when the research result publish researchers may obtain

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Estrone
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs